![]() |
home | contact us | sitemap |
||
![]() |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
||
![]() |
![]() ![]() ![]() ![]() ![]() ![]() |
![]() |
|
Formula’s R&D plan consists of allogeneic CIK-CAR.CD19 for B cell malignancies, followed closely by the development of allogeneic CIK-CAR.CD33 for myeloid leukemias. Within the area of solid tumors, Formula plans to develop a CIK-CAR.PSMA program and other proprietary targets. Formula is also developing a proprietary target for Multiple Myeloma. Formula’s R&D pipeline as of December 2016
|
![]() |
|||
Copyright 2015 Formula Pharmaceuticals, Inc. LEGAL NOTICES | PRIVACY POLICY Page Updated: 02/27/2017 10:01:23 AM |
|